| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
| Targets |
Hythiemoside B, as an ent-pimarane glucoside, may exert its biological effects through multiple mechanisms. Ent-pimarane-type diterpenoids are known to exhibit various biological activities including anti-inflammatory, immunomodulatory, and anticancer effects. The glucoside moiety may influence the compound's solubility, stability, and bioavailability. However, specific pharmacological targets for Hythiemoside B have not been identified.
|
|---|---|
| ln Vitro |
In vitro, Hythiemoside B has been studied for its chemical properties and potential biological activities. As an ent-pimarane glucoside, it may exhibit anti-inflammatory, immunomodulatory, or other activities. However, specific in vitro activity data for Hythiemoside B are limited. The compound is primarily characterized as a natural product for research purposes.
|
| ln Vivo |
In vivo, Hythiemoside B has not been extensively studied as a therapeutic agent. As a natural product from Siegesbeckia orientalis, which has traditional medicinal uses, the compound may have potential therapeutic applications. However, specific in vivo data for Hythiemoside B are lacking. The compound is primarily used as a research tool for studying ent-pimarane diterpenoids.
|
| Enzyme Assay |
Non-cell-based assays for Hythiemoside B involve characterization of its chemical properties. The compound's structure is confirmed by NMR and MS. Its purity is determined by HPLC. The compound's chemical properties including molecular formula (C₂₈H₄₆O₉) and molecular weight (526.7) are characterized. Its solubility and stability are characterized for research applications.
|
| Cell Assay |
Cellular assays for Hythiemoside B are performed using various cell lines. Cells are treated with the compound at various concentrations, and cellular responses are measured. Cell viability is measured by MTT assays. Anti-inflammatory activity is evaluated by measuring pro-inflammatory cytokine production and NF-κB activation. Immunomodulatory effects may be assessed by measuring immune cell proliferation and cytokine production. However, specific data are limited.
|
| Animal Protocol |
In vivo experiments with Hythiemoside B are limited as the compound is primarily used as a research tool. Animal studies may involve administration of the compound to evaluate its biological effects. However, detailed in vivo data are not available. The compound is for research use only and is not intended for human consumption.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of Hythiemoside B have not been characterized. As a diterpenoid glucoside with a molecular weight of 526.7, the compound is expected to have moderate oral bioavailability. Its absorption, distribution, metabolism, and excretion are not defined. The compound's stability in biological matrices and its metabolic fate are not known. Comprehensive PK studies are lacking.
|
| Toxicity/Toxicokinetics |
The toxicity profile of Hythiemoside B has not been comprehensively evaluated. As a natural product from Siegesbeckia orientalis, which has traditional medicinal uses, the compound is generally considered to have low toxicity. However, comprehensive toxicological studies including genotoxicity, organ toxicity, and maximum tolerated dose have not been fully characterized. The compound is for research use only.
|
| References | |
| Additional Infomation |
Hythiemoside B has been reported to have been found in Wollastonia biflora, Sigesbeckia orientalis, and Indocypraea montana, with relevant data available for reference.
Hythiemoside B (CAS# 853267-90-0) is an ent-pimarane glucoside with the molecular formula C₂₈H₄₆O₉ and a molecular weight of 526.7. It is isolated from the aerial parts of Siegesbeckia orientalis L. (Asteraceae). The compound is a new ent-pimarane-type diterpenoid glucoside and is isolated as a white amorphous powder. As of current knowledge, Hythiemoside B is not approved as a therapeutic agent. |
| Molecular Formula |
C28H46O9
|
|---|---|
| Molecular Weight |
526.659450054169
|
| Exact Mass |
526.314
|
| CAS # |
853267-90-0
|
| PubChem CID |
11203296
|
| Appearance |
Typically exists as solid at room temperature
|
| LogP |
2.2
|
| Hydrogen Bond Donor Count |
5
|
| Hydrogen Bond Acceptor Count |
9
|
| Rotatable Bond Count |
7
|
| Heavy Atom Count |
37
|
| Complexity |
874
|
| Defined Atom Stereocenter Count |
11
|
| SMILES |
CC(=O)O[C@@H](CO)[C@]1(CC[C@@H]2C(=C1)CC[C@H]3[C@]2(CC[C@H](C3(C)C)O[C@H]4[C@@H]([C@H]([C@@H]([C@H](O4)CO)O)O)O)C)C
|
| InChi Key |
POOFTLXTGZSZGA-AUNXJCHXSA-N
|
| InChi Code |
InChI=1S/C28H46O9/c1-15(31)35-21(14-30)27(4)10-8-17-16(12-27)6-7-19-26(2,3)20(9-11-28(17,19)5)37-25-24(34)23(33)22(32)18(13-29)36-25/h12,17-25,29-30,32-34H,6-11,13-14H2,1-5H3/t17-,18-,19-,20-,21+,22-,23+,24-,25+,27+,28+/m1/s1
|
| Chemical Name |
[(1R)-1-[(2S,4aR,4bS,7R,8aS)-2,4b,8,8-tetramethyl-7-[(2R,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-4,4a,5,6,7,8a,9,10-octahydro-3H-phenanthren-2-yl]-2-hydroxyethyl] acetate
|
| Synonyms |
Hythiemoside B
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.8988 mL | 9.4938 mL | 18.9876 mL | |
| 5 mM | 0.3798 mL | 1.8988 mL | 3.7975 mL | |
| 10 mM | 0.1899 mL | 0.9494 mL | 1.8988 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
